Interventional Glaucoma

Researchers at the University of Strathclyde have developed an affordable device which takes 3D images and could shift the landscape of eye screening and treatment around the world.

The program — entitled “Pumping Adrenaline!” — brings viewers myriad challenging cases, intraoperative complications, and complex problems following cataract surgery.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Ehsan Sadri, MD FACS, A minimally invasive glaucoma surgery specialist discusses impressions and key take away points from patient case.

Ehsan Sadri, MD FACS reviews the case of a 67-year-old white female with open angle glaucoma and how she benefits from minimally invasive glaucoma surgery.

A minimally invasive glaucoma surgery specialist discusses impressions and key take away points from patient case and how minimally invasive glaucoma surgery has changed the landscape of open angle glaucoma.

Ehsan Sadri, MD, FACS, reviews the case of a 58-year-old male with open angle glaucoma utilizing minimally invasive glaucoma surgery procedure.

The research from eye care nonprofit Orbis International focuses on diabetic retinopathy in Rwanda, where associated vision complications from diabetes are growing.

Automated 360-degree goniophotography seems to have simplified screening and diagnosis of glaucoma.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Investigators find the recognition could improve surveillance of the disease.

The 10-week Flying Eye Hospital program will offer courses focusing on advanced glaucoma and simulation lectures for residents.

Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.

Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.

Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.

Joseph Panarelli, MD, and Arsham Sheybani, MD, discuss the Primary Trabeculectomy for Advanced Glaucoma: Pragmatic Multicentre Randomized Controlled Trial, or TAGS trial, and how this can apply to real world situation. This multicenter randomized controlled trial evaluated whether primary trabeculectomy or primary medical treatment leads to improved outcomes in terms of quality of life, clinical effectiveness, and safety.

Investigators from the New York University Grossman School of Medicine presented data at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation, and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

Kevin Waltz, a consultant for ViaLase, discusses the company's technology: an image-guided femtosecond laser surgical system for the treatment of glaucoma.

Ophthalmologists have seen a progression in cyclophotocoagulation (CPC), with each generation becoming more doctor and patient friendly. Shan C. Lin, MD, a glaucoma specialist at the Glaucoma Center of San Francisco in California, described the advances in the technology.

Tom Frinzi, executive chairman of ViaLase, a new company based in Orange County, gives an update on the company, sharing some exciting new things happening.

The glaucoma market seems to be in an expansion phase, as evidenced by the explosions in the number of new pharmaceutical and surgical options entering the marketplace. The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market.

About 65% of patients sought follow-up care for glaucoma after presentation to the Wills Eye Hospital emergency room (ER), according to Elliot G. Cherkas, BSc, the lead author of the study.

Orbis' Nicolas Jaccard, PhD, principal AI architect, discusses the impact that AI can have on health care, including current applications for AI in glaucoma, the challenges of acceptance of AI in clinical settings, how AI has helped with the diagnosis of glaucoma, and the vision for the future of AI in glaucoma and eye care in general.

NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470

Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.

Device demonstrates potential as a durable, sustained-release glaucoma therapy

The company announced the expansion of its commercial rollout of its MIGS implant to the UK

A University of Houston study found that minorities have fewer eye exams, higher instances of disease.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.